The company, which is part of the Nasdaq Biotech Index, will ring the bell on January 13.
“2019 was a momentous year for Co-Diagnostics,” said CEO Dwight Egan in a statement.
Egan noted that the company had achieved several milestones in 2019. They include:
- the completion and CE marking of its first multiplex diagnostic for Zika/dengue/chikungunya;
- the launch of several multiplex tests for the mosquito abatement market, which helped the company record its first domestic revenue;
- the expansion of a license agreement with LGC, Biosearch Technologies for Co-Diagnostics’ CoPrimer technology; and
- the inauguration of its joint venture manufacturing facility in India, followed by the IVD approval for five diagnostic assays from the Indian equivalent of the US Food and Drug Administration.
“We extend our gratitude to all shareholders, investors, customers, and partners for their support, and hope you will join us as we build on these milestones to make 2020 the best year yet for CODX,” he added.
Salt Lake City, Utah-based Co-Diagnostics is a molecular diagnostics company that develops and markets advanced diagnostics technology.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham